Reports First Quarter 2020 Results NASDAQ:CNSP, NASDAQ:GNPX, NASDAQ:ARPO, NASDAQ:NMTR

CNS PHARMACEUTICALS (NASDAQ:CNSP) EARNINGS INFORMATION (NASDAQ:CNSP)

CNS Pharmaceuticals last announced its quarterly earnings data on May 14th, 2021. The reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.03. CNS Pharmaceuticals has generated ($0.57) earnings per share over the last year (($0.60) diluted earnings per share). Earnings for CNS Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.68) per share. CNS Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, August 16th, 2021 based off prior year’s report dates.

IS CNS PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:CNSP)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for CNS Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should “buy” CNS Pharmaceuticals stock.
CNS Pharmaceuticals

GENPREX (NASDAQ:GNPX) EARNINGS INFORMATION (NASDAQ:GNPX)

Genprex last posted its earnings data on May 16th, 2021. The reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. Genprex has generated $0.00 earnings per share over the last year (($0.61) diluted earnings per share). Genprex has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 17th, 2021 based off prior year’s report dates.

IS GENPREX A BUY RIGHT NOW? (NASDAQ:GNPX)

1 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” Genprex stock.
Genprex

AERPIO PHARMACEUTICALS (NASDAQ:ARPO) EARNINGS INFORMATION (NASDAQ:ARPO)

Aerpio Pharmaceuticals last issued its earnings results on August 10th, 2021. The reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.31. Aerpio Pharmaceuticals has generated ($0.10) earnings per share over the last year (($0.08) diluted earnings per share). Earnings for Aerpio Pharmaceuticals are expected to decrease in the coming year, from ($1.39) to ($1.82) per share. Aerpio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 9th, 2021 based off prior year’s report dates.

IS AERPIO PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:ARPO)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Aerpio Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Aerpio Pharmaceuticals stock.
Aerpio Pharmaceuticals

9 METERS BIOPHARMA (NASDAQ:NMTR) EARNINGS INFORMATION (NASDAQ:NMTR)

9 Meters Biopharma last issued its quarterly earnings data on August 11th, 2021. The reported ($0.03) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.03). 9 Meters Biopharma has generated ($0.58) earnings per share over the last year. Earnings for 9 Meters Biopharma are expected to grow in the coming year, from ($0.14) to ($0.10) per share. 9 Meters Biopharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

IS 9 METERS BIOPHARMA A BUY RIGHT NOW? (NASDAQ:NMTR)

8 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for 9 Meters Biopharma in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” 9 Meters Biopharma stock.
9 Meters Biopharma